Form 4: Iovance Biotherapeutics COO Igor Bilinsky Reports RSU Vesting and Tax-Related Share Disposition

Iovance Biotherapeutics' Chief Operating Officer, Igor Bilinsky, reported the vesting of 12,305 restricted stock units and the subsequent disposition of 6,250 shares for tax withholding purposes, resulting in a net beneficial ownership of 93,633 common shares.

Summary

• Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc. (IOVA), reported transactions on June 2, 2025.
• 12,305 shares of common stock were acquired due to the vesting of restricted stock units (RSUs) at a price of $0.
• Concurrently, 6,250 shares of common stock were disposed of at a price of $1.76 to satisfy mandatory tax withholding requirements upon RSU vesting. This was not an open market sale.
• Following these transactions, Mr. Bilinsky beneficially owns 93,633 shares of common stock directly.
• Derivative securities transactions included the vesting of 3,516 RSUs (from a March 2, 2023 grant) and 8,789 RSUs (from a March 1, 2024 grant).
• After these vestings, Mr. Bilinsky holds 10,549 remaining RSUs from the March 2, 2023 grant and 61,528 remaining RSUs from the March 1, 2024 grant.
• The remaining RSUs are scheduled to vest in equal quarterly installments.

Sentiment

Score: 7

Explanation: The document reflects a routine and expected compensation event for a company executive. The vesting of RSUs is a positive for the individual, indicating value realization, while the tax withholding is a standard procedure. There are no unexpected negative or positive surprises for the company or its stock price.

Positives

• Vesting of 12,305 restricted stock units (RSUs) indicates compensation realization for the Chief Operating Officer.
• The acquisition of shares through RSU vesting at a $0 exercise price is a common and beneficial form of equity compensation.

Negatives

• 6,250 shares were disposed of to cover mandatory tax withholding, reducing the direct share ownership.

Future Outlook

The document indicates that remaining Restricted Stock Units (RSUs) will vest in equal quarterly installments, providing a future schedule for additional share acquisitions by the reporting person.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation, which is a common practice across all industries, including the biotechnology sector where Iovance Biotherapeutics operates. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine insider compensation event and is unlikely to have a significant direct impact on the share price or company valuation. It provides transparency into executive equity ownership.
• Employees: Reflects standard equity compensation practices for executives, which can be a positive signal regarding employee incentives.

Next Steps

• Remaining Restricted Stock Units (RSUs) from the March 2, 2023, and March 1, 2024, grants will continue to vest in equal quarterly installments.

Key Dates

Recommendation

Keywords

Iovance Biotherapeutics, IOVA, Igor Bilinsky, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Chief Operating Officer, Share Ownership, Tax Withholding